Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co. (NYSE: MRK) is a global pharmaceutical leader with a 350-year legacy of medical innovation. This news hub provides investors and healthcare professionals with direct access to official announcements, financial disclosures, and research developments shaping the company's trajectory.
Track MRK's latest regulatory milestones, clinical trial results, and strategic partnerships through verified press releases and curated analysis. Our repository includes earnings call transcripts, FDA approval updates, and global health initiatives—all organized for efficient research and due diligence.
Key updates on therapeutic advancements in oncology, vaccines, and infectious diseases are maintained alongside financial performance data. Bookmark this page for real-time access to Merck's corporate communications and market-moving developments in the pharmaceutical sector.
Merck (NYSE: MRK) has declared a quarterly dividend of
Perceiv AI has been chosen for the inaugural cohort of the Merck Digital Sciences Studio (MDSS), receiving funding and mentorship from Merck (NYSE: MRK), Northpond Ventures, and McKesson Ventures. This selection, announced on January 17, 2023, is a significant milestone for Perceiv AI, highlighting their innovative prognostic platform that integrates multimodal data to address neurodegenerative diseases. The MDSS program aims to enhance drug discovery and development through collaborations and access to advanced technology. Perceiv AI plans to expand its ForesightTM platform to develop biomarkers for conditions like Alzheimer's disease.
Merck (NYSE: MRK) has successfully completed its cash tender offer for all outstanding shares of Imago BioSciences (NASDAQ: IMGO) at $36.00 per share. The offer expired on January 10, 2023, with 31,307,028 shares validly tendered, representing approximately 89.2% of Imago’s total outstanding shares. Following the acquisition, Imago will merge into Merck's subsidiary, becoming a wholly owned subsidiary, and its shares will be delisted from Nasdaq.
Merck (NYSE: MRK) will host its fourth-quarter and full-year 2022 earnings call on February 2 at 8:00 a.m. ET. Executives will review company performance and future outlook. The call will be accessible via a weblink and through phone lines at (888) 769-8514 in the U.S. and (517) 308-9208 internationally. A replay will also be available on Merck's website.
Merck (NYSE: MRK) has announced that Robert M. Davis, CEO, and Dr. Dean Y. Li, President of Merck Research Laboratories, will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 5:15 PM PT / 8:15 PM ET. A live audio webcast of the presentation will be available for investors and the public.
Merck is committed to advancing healthcare through research and innovation, focusing on developing medicines and vaccines to improve lives globally.
Merck (NYSE: MRK) announced that CEO Robert M. Davis will participate in a fireside chat at the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, Jan. 5, 2023, at 8:55 a.m. ET. Investors, analysts, and the public can access the live video webcast here.
Merck (NYSE: MRK) and Kelun-Biotech have entered an exclusive collaboration to develop seven investigational preclinical antibody-drug conjugates (ADCs) for cancer treatment. The agreement includes an upfront payment of $175 million to Kelun-Biotech, with potential future milestone payments totaling $9.3 billion if all candidates achieve regulatory approval. Merck gains global licenses for these ADC therapies while Kelun retains rights in China, Hong Kong, and Macau. This partnership builds on earlier collaborations for two ADC candidates, aiming to enhance Merck's oncology pipeline.
FAQ
What is the current stock price of Merck & Co (MRK)?
What is the market cap of Merck & Co (MRK)?
